Intravenous Mepolizumab In Subjects With Hypereosinophilic Syndromes (HES)
NCT00086658
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
86
Enrollment
INDUSTRY
Sponsor class
Conditions
Hypereosinophilia
Hypereosinophilic Syndrome
Interventions
DRUG:
mepolizumab
Sponsor
GlaxoSmithKline